Medicare ‘Small Biotech’ Exemption Could Mostly Help Products That Are Neither, PCMA Warns

The exemption could be sought for small molecule drugs covered by Medicare Part D that have high levels of spending and are marketed by large companies, the Pharmaceutical Care Management Association suggests.